Earlier this year, Senator Elizabeth Warren introduced a bill that she said would provide billions of new dollars for medical research. The Massachusetts Democrat proposed that if large pharmaceutical companies are caught breaking laws, any settlements they reach with the federal government should include paying into a fund that would benefit the NIH. Warren says that such a ''swear jar,'' as she calls her Medical Innovation Act, would have provided roughly $6 billion a year to the NIH research budget had it been the law over the last five years.
Pharmaceutical companies oppose the measure, and it's not clear that it will pass. But it does call attention to a problem people in the biomedical research field agree exists, a shrinking pool of government money for funding science. Though Congress doubled the NIH budget between 1998 and 2003, it's been contracting ever since, dropping by more than 22 percent in inflation-adjusted dollars, according to the Federation of American Societies for Experimental Biology. Public funding for scientific research has dropped in Europe as well, as governments imposed austerity measures in response to the 2008 fiscal crisis. ''I think all countries are struggling with their budgets,'' says Birgitte Nauntofte, executive director of the Novo Nordisk Foundation in Hellerup, Denmark. ''I have not heard of a country that's not struggling.'' So researchers are looking to another source of funding-corporations. Whether through sponsored research agreements, innovative ideas about investment funds focused on science, or Denmark's tax model that allows the Novo Nordisk Foundation to support scientists, companies are picking up the tab for science that's not being covered by public funds.
The Whitehead Institute for Biomedical Research, in Cambridge, MA, for instance, has turned to more sponsored research to cover its overall research budget, which has stayed at roughly $60 million for the past decade, adjusting for inflation. ''Ten years ago the majority of that funding came from federal sources, and today it's no more than a third,'' says Richard Young, a member of the institute who studies the regulatory circuitry that controls gene expression.
To make up for that drop in government grants, the Whitehead looks to other sources-philanthropy, royalties on patents, and sponsored research agreements. Last year, for instance, Whitehead announced it had signed a 3-year deal in which the biotechnology company Biogen would provide $5.25 million to fund basic research in immunology, neurology, developmental biology, genetics, and genomics. ''That's basically an R01 level of funding,'' says Mark Muskavitch, senior director of epigenetics at Biogen, making Biogen's support for a given project comparable to the NIH's. He runs a consortium that also includes researchers from Harvard Medical School, Brigham and Women's Hospital, Institut Pasteur in Paris, and Washington University in St. Louis, MO, and focuses on the biology of neurodegeneration. Biogen is also funding other consortia looking at amyotrophic lateral sclerosis, scleroderma, fibrosis, and sickle cell anemia.
''Biogen has been and wants to remain an innovative company, and innovation comes from research,'' Muskavitch says. These are not, he stresses, outsourced corporate research and development programs, aimed at producing products for the company. ''It's not exactly blue sky, but only secondarily are we trying to move in limited cases into translational work,'' he says. ''We're trying to encourage basic research with an eye toward translatability but not a requirement for translation.'' That said, the company is putting its money into areas of biology where its markets lie, such as treatment for Alzheimer's or Parkinson's disease. Muskavitch says in selecting the projects to fund within the Whitehead, he has ''encouraged but not constrained'' the researchers to lean toward neurobiology.
To receive Biogen funding, Whitehead researchers go through a grant-writing and approval process that's similar to applying for NIH money, though dealing with the company is simpler than dealing with the government, Young says. ''I would say that relationship we have with Biogen is probably an easier, more friendly, more productive relationship than a comparable one with NIH,'' he says.
Whitehead takes care to maintain independence in its scientific work. If the Institute has a substantial financial interest in a company, it won't take funding from that company. And none of the research can be secret. ''We have to be able to publish what we learn. We can't have a restriction on publication,'' Young says. The same applies to government funding; Whitehead won't accept Department of Defense funding that comes with publication restrictions.
What Whitehead does provide to funders is an advance look at research results, often for a 30-day period, as long as that doesn't delay publication. Under some agreements, companies also have a right of first refusal over any intellectual property the Whitehead develops. Another benefit to corporations that sponsor research is developing relationships with scientists who work in research areas of interest to those companies. ''Components of every major pharma are here in the Boston area because they want to be close to that human capital,'' Young says.
In Denmark, the Novo Nordisk Foundation also tries to use it funds to generally support basic research and to develop experts, while still having an eye on advances that could benefit its areas of specialization, which include diabetes, hemophilia, and hormone replacement therapy. ''The overall goal of our grants is we would like to develop what we call a knowledge-based society,'' says Nauntofte. ''We also want to help foster a world class educational system.''
The foundation provides grants totaling 785 million Danish krone (US $113 million), and plans to increase that to 1.5 billion krone (US $216 million) by 2018. Half of that goes to support health-related science, with focuses on endocrinology and metabolic physiology. Another 20% goes to biotechnology, including finding new methods for synthesis and production. About 10% goes to education and another 10% to humanitarian purposes, even art history. And roughly 4% goes to supporting research that could lead researchers to start their own companies. The foundation has established centers for metabolic research, biosustainability, protein research, and basic stem cell biology. It also founded the Danish National Biobank to collect biological samples from the population at large.
The Danish foundation structure is unusual, Nauntofte says. Foundations, often created by the founders of successful companies, actually own their companies and receive tax benefits for giving away a percentage of their profits. ''Some of our best-performing companies are owned by private foundations and it's quite unique to our country,'' Nauntofte says. She estimates that approximately 80 percent of what Denmark spends on research comes from the government and about 10 percent comes from private foundations. Another 7 percent comes from European and American funding agencies, with private companies covering the other 3 percent.
The Novo Nordisk Foundation maintains a controlling interest in the publicly traded pharmaceutical company, Novo Nordisk A/S, and Novozymes, a biotechnology company that manufactures enzymes. While the public company invests in other life-science companies, the foundation controls the grant process. The process is similar to that of any funding agency, with calls for applications, deadlines, and a review by a panel of experts, none of whom can be Novo Nordisk employees. But once the award are granted, Nauntofte says, there are no strings attached. ''They're all donations, they have no restrictions,'' she says. ''The researchers have full freedom. We give the money away and it's all theirs.'' Søren Molin, a systems biologist at the Technical University of Denmark, in Lyngby, receives about $1 million of funding a year as scientific director of the bacterial cell factories section of the foundation's Center for Biosustainability. ''We have the obligation in the contract that we have to produce science of the greatest impact and the greatest quality,'' he says. ''The other obligation we have is to burn the money.'' The recipients have to spend the funds, not save or invest it or return it to the foundation.
The center was created in 2010 after the foundation approached the university and asked them to propose a project that could be labeled ''biosustainability.'' Beyond that initial direction, Molin says, the foundation does not tell scientists what work to do. ''We are doing biotech but not necessarily the kind of biotech that Novo Science is doing,'' Molin says, though he adds, ''Some of the research and technology we're doing might be useful and benefit the company eventually.'' He doesn't think the center, which will receive nearly $160 million over 10 years, would exist if it had to rely on Danish funding agencies. ''There would be no way in this country that any research council could spend this kind of money toward a specific issue,'' he says.
In countries that don't have Denmark's tax structure, there are still creative ways to funnel corporate cash into research. Google, for instance, formed a biotechnology company, Calico, in 2013 to focus on diseases of aging, including neurodegeneration and cancer, with an initial investment of $240 million and the promise of up to another $490 million. Calico hired Arthur Levinson, former CEO of Genetech, to run the company and brought other highly respected scientists on board. Last year, Calico joined forces with the biopharmaceutical company AbbVie to create an R&D collaboration, with AbbVie contributing $750 million. Calico declined requests for an interview. Meanwhile, Google's research arm, Google X, has a life sciences division, which is developing wearable health sensors and planning to collect genetic and molecular information from thousands of people. The Wall Street Journal last July reported that the life sciences division had built a team of 70 to 100 experts in areas such as physiology, biochemistry, optics, imaging, and molecular biology.
But turning to individual companies might not be the only way to find money for science. Andrew Lo, a professor of Finance at MIT's Sloan School of Management, proposes creating investment funds, not unlike the mutual funds in which people invest their IRAs. There's a gap, he says, between the basic research funded by the government, and potentially marketable therapies, supported by biopharmaceutical investors once they've made it through Phase 2 of clinical trials. He'd like to fill that gap with megafunds, large pools of investment dollars that could support research in places like the Whitehead.
A megafund, Lo explains, might pick out the top 50 or so biomedical research institutions in the country, and invest in five or 10 labs in each center. The labs could be selected by an expert review committee, and some could be culled from the fund based on progress reports. Beyond that review, the researchers would have free rein, with the stipulation that if they developed anything marketable, investors would receive 8 percent of the royalties. If such an investment produced only one or two new multi-million-dollar drugs, it would pay off handsomely. ''It only takes one or two cancer drugs to generate profits, but you pay for all of the losses in a diversified portfolio,'' Lo says.
In a paper published in Nature Biotechnology in 2012, Lo ran a simulated fund based on historical data from the previous two decades and estimated that a fund of $5 billion to $15 billion could generate a return of anywhere from 5 to 12 percent, depending on how it was set up. In a separate simulation, he found that a megafund taking advantage of orphan drug rules could generate a return in double digits if it invested $575 million in from 10 to 20 projects. He points to the Cystic Fibrosis Foundation, which gave the drug company Vertex $150 million. Vertex developed a treatment for CF, and last year the CF foundation sold the royalties from that drug for $3.3 billion, which it can now apply to further research.
''It could be a more sustainable way for science to become self-supporting,'' says Lo, who expects that small versions of a megafund could arise within the coming year.
All this talk of corporate funding may lead to worries about privatizing science, with government leaving support of research to the private sector. Molin, for example, says that since he received money from the Novo Nordisk Foundation, it's been harder for him to get grants from Danish research councils-he does better with European Union funders. ''It's going to be an interesting situation to see within say the next five years how the balance will be between private and public funding of research, Molin says. ''If this balance is too biased in one direction, it's not so healthy.'' Nauntofte says that most policymakers realize that providing a stable research and educational system is the purview of federal governments. ''The idea is of course not to substitute for the government, the idea of the foundation is to make supplements,'' she says.
Muskavitch doesn't believe corporate dollars can make up for lack of federal investment in research, and he worries about the fact that investment has been shrinking. ''NIH has become dysfunctional, and the scientific enterprise in the US is at great risk going forward in remaining at the leading edge of biological discovery and other discovery,'' he warns.
And Young argues that basic research, which not only provides new discoveries but also acts as an economic engine, needs public support. ''The federal government has the responsibility of ensuring that that basic research is healthy,'' Young says. ''The system is really highly dependent on the government recognizing its role.''
